Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity G Medical Innovations Holdings Limited		
<b>ARBN</b> 617 204	743	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Professor Zeev Rotstein
Date of last notice	8 March 2019

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct; and 2. Indirect.	
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Held via IBI Trust Management, the trustee for G Medical's ESOP.	
Date of change	18 July 2019	
No. of securities held prior to change	1. Nil 2. 371,976 Unlisted Options (US\$0.00001, 5 February 2022)**	
Class	Performance Rights	
Number acquired	500,000	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation  No. of securities held after change	Nil consideration. Estimated valuation \$97,500, based on closing price of GMV shares on 17 July 2019, on assumption vesting condition will be met in the future.  1. 500,000 Performance Rights	
	2. 371,976 Unlisted Options (US\$0.00001, 5 February 2022)	

<sup>+</sup> See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Securities issued to director in accordance with resolution passed at the Annual General Meeting.
---	---

<sup>\*\*</sup> Note the 371,976 Unlisted Options (US\$0.00001, 5 February 2022) were incorrectly disclosed as a direct holding in the Director's 3X lodged with the ASX on 8 March 2019. These options have been held indirectly with IBI Trust Management since 9 May 2018.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

## Part 3 – <sup>+</sup>Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
1	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.